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In 271 Enterobacter blood culture isolates from 12 hospitals, extended-spectrum beta-lactamase (ESBL)
prevalence varied between 0% and 30% per hospital. High prevalence was associated with dissemination,
indicating the potential relevance of infection control measures. Screening with cefepime or Vitek 2, followed
by a cefepime/cefepime-clavulanate Etest, was an accurate strategy for ESBL detection in Enterobacter isolates
(positive predictive value, 100%; negative predictive value, 99%).
No guidelines have been issued for extended-spectrum beta-
lactamase (ESBL) detection in members of the Enterobacteri-
aceae with inducible chromosomal AmpC beta-lactamases,
such as Enterobacter spp., although these species may cause
hospital outbreaks (7, 9, 10), are frequently multidrug resistant
(MDR) (9, 10), and may constitute a reservoir for plasmid-
mediated ESBLs (3, 12, 13) for other Enterobacteriaceae spe-
cies. The absence of such recommendations likely has two
reasons. First, phenotypic detection of ESBLs in members of
the Enterobacteriaceae coexpressing an AmpC beta-lactamase
is complex, because AmpC expression may mask the synergy
required for ESBL detection between third-generation cepha-
losporins and clavulanic acid. This problem may be circum-
vented by demonstrating synergy between clavulanic acid and
cefepime, a fourth-generation cephalosporin hydrolyzed by
ESBLs but generally not by AmpC beta-lactamases (11, 13).
Second, the outcome of an ESBL detection test in Enterobac-
teriaceae spp. with inducible AmpC is considered of limited
therapeutic consequence, since most clinicians consider ceph-
alosporins, including cefepime, inappropriate for treatment of
infections caused by these species (6, 8). As a result, data are
sparse on ESBL prevalence in Enterobacteriaceae spp. with
inducible chromosomal AmpC beta-lactamases.
The aims of this study were (i) to develop a phenotypic
ESBL detection strategy in Enterobacter species for the routine
clinical laboratory and (ii) to determine whether infection con-
trol measures could potentially reduce the ESBL prevalence in
Enterobacter species by assessing the association between prev-
alence and clonal relatedness of ESBL-positive isolates per
hospital.
For this study, all Enterobacter blood culture isolates (one
per patient) obtained in 2006 and 2007 from 12 Dutch labora-
tories were included. Identification was performed by the par-
ticipating laboratories using either Vitek 2 (bioMe´rieux,
France) or Phoenix (Becton Dickinson). A total of 271 blood
culture isolates were included; 227 (84%) were Enterobacter
cloacae and 44 (16%) were Enterobacter aerogenes. Based on
detection of TEM, SHV, and CTX-M ESBL genes by sequenc-
ing, 37 (14%) were ESBL producers (36 E. cloacae isolates and
1 E. aerogenes isolate). The most prevalent ESBL genes were
CTX-M-9 (54%) and SHV-12 (38%), in accordance with re-
sults from previous studies (1, 7, 9, 13). CTX-M-15, CTX-M-3,
and CTX-M-39 were each detected once.
To develop a phenotypic ESBL detection strategy, the Vitek
2 advanced expert system (AES) (version 5.01; AST N048
cards) and MIC breakpoints of several indicator cephalospo-
rins were evaluated, using detection of ESBL genes as the
reference test. Susceptibility testing was performed by broth
microdilution (BMD), except for cefpodoxime (Etest; bio-
Me´rieux, Marcy l’Etoile, France), using CLSI and EUCAST
breakpoints. As a confirmatory phenotypic test, the PM/PML
Etest (cefepime/cefepime plus clavulanic acid) was evaluated.
The test characteristics of the ESBL screening methods
based on different cephalosporin MICs and the Vitek 2 AES
are shown in Table 1. For all cephalosporins included, the
MIC-based screening method provided a sensitivity and nega-
tive predictive value (NPV) of 100%. Using the Vitek 2 AES,
the sensitivity was 92% (34/37) and the NPV was 99% (203/
206). However, since a cefepime MIC of 1 mg/liter as deter-
mined by BMD (Fig. 1) or an ESBL warning of the Vitek 2
AES had the highest specificity (86 to 87% versus 37 to 68%
for the other methods), these screening methods performed
best. The relative high specificity will require a lower number
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of ESBL confirmation tests of the isolates (25% versus 42 to
68%) compared to the indicator cephalosporins recommended
by CLSI for ESBL screening in Escherichia coli and Klebsiella
spp. (Table 1).
It should be noted that a cefepime MIC of 1 mg/liter
measured with BMD methodology was 100% sensitive, while a
cefepime MIC of 1 mg/liter measured with Vitek 2 had a
sensitivity of 54% (P  0.001) (data not shown). This differ-
ence is explained by significantly lower cefepime MIC results
from Vitek 2 compared to those from BMD (a MIC90 of 2
mg/liter versus a MIC90 of 16 mg/liter, respectively; P 
0.001), as reported by others (5).
The PM/PML Etest was evaluated as a confirmatory test on
124 isolates with a BMD MIC of ceftriaxone of 1 mg/liter
and/or a MIC of ceftazidime of 1 mg/liter. The test charac-
teristics were as follows: sensitivity, 86% (32/37); specificity,
95% (83/87); positive predictive value (PPV), 100% (32/32);
and NPV, 99% (83/84). The test result was false negative in
one CTX-M-9-positive isolate and off range in eight isolates, of
which four contained an ESBL gene. These test characteristics
are in line with a previous report using the less-expensive
cefepime-clavulanate combination disks (13).
The ESBL prevalence varied between 0% and 30% per
hospital (Fig. 2). A prevalence of 14% was observed in 6
hospitals. DiversiLab strain typing (4) demonstrated that a
high prevalence was associated with a high level of clonality of
E. cloacae in 5 hospitals (Fig. 2). All isolates within a single
clonal lineage carried the same ESBL gene. Interestingly, in 5
of the 7 hospitals with different strain types, only one ESBL
genotype was found, either exclusively SHV-12 or CTX-M-9,
suggesting that plasmid transfer may have occurred. The ESBL
prevalence in Enterobacter spp. was almost twice as high as the
ESBL prevalence in invasive E. coli and Klebsiella pneumonia
isolates from the same period in the Netherlands (4.7% and
6.9%, respectively [http://www.rivm.nl/earss/database/]). A
likely explanation for this difference was the lack of a labora-
tory protocol for ESBL detection in Enterobacter spp., resulting
in a lack of infection control measures and thus an increased
likelihood of nosocomial spread.
All isolates were susceptible to meropenem, imipenem, and
TABLE 1. Test characteristics of screening methods for ESBL production in 271 Enterobacter isolates (37 ESBL positive; 234 ESBL
negative), using genotypic detection of ESBL as the reference methoda
ESBL screening method MIC (mg/liter) Sensitivity (%) Specificity (%) PPV (%) NPV (%) Isolates meeting screeningcriteria (% of all isolates) (n  271)
Broth microdilution
Ceftriaxoneb and/or ceftazidimeb 1 100 63 30 100 124 (46)
Cefotaximeb and/or ceftazidime 1 100 68 33 100 113 (42)
Cefpodoximeb 4 100 37 20 100 185 (68)
Cefepime 1 100 86d 53d 100 70 (26)d
Vitek 2
AES “ESBL production” 92c 87d 52d 99c 65 (24)d
a PPV, positive predictive value; NPV, negative predictive value; AES, advanced expert system.
b Indicator cephalosporins and ESBL screening breakpoints recommended by CLSI for ESBL screening in E. coli, Klebsiella spp., and Proteus mirabilis. These
breakpoints are equivalent to the EUCAST clinical susceptible/intermediate breakpoints, except for cefpodoxime (EUCAST susceptible breakpoint, 1 mg/liter).
c P  0.05 for comparison of sensitivity and NPV between Vitek 2 AES and the broth microdilution ESBL screening methods. Three ESBL-producing E. cloacae
isolates (2 CTX-M-9, 1 SHV-12) were identified as ESBL-positive “high-level cephalosporinase” producers instead of ESBL producers.
d P  0.001 for comparison of specificity, PPV, and number of isolates meeting screening criteria between Vitek 2 AES or the MIC of cefepime (1 mg/liter) and
the other broth microdilution ESBL screening methods.
FIG. 1. Distribution of cefepime MICs in Enterobacter blood culture isolates. *, 0% of the ESBL positive isolates and 86% of the ESBL negative
isolates were susceptible to cefepime using the EUCAST breakpoint. **, 8% of the ESBL positive isolates and 94% of the ESBL negative isolates
were susceptible to cefepime using the CLSI breakpoint. S/I, susceptible/intermediate.
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tigecycline. Of the ESBL-producing isolates, 40% were MDR,
i.e., simultaneously resistant to ciprofloxacin, cotrimoxazole,
and tobramycin or gentamicin, versus 3% in the non-ESBL
isolates. Of the 4 ESBL-positive strains involved in clonal dis-
semination (Fig. 2), 3 were MDR, including the 2 clones that
were detected in different hospitals (genotypes 104 and 85). An
increasing prevalence of MDR strains will augment the use of
carbapenems, an undesirable development in the face of the
worldwide emergence of carbapenemase-producing Enterobac-
teriaceae isolates (2).
In conclusion, the results of this study provide a practical
and accurate strategy for phenotypic detection of ESBLs in
Enterobacter spp. We recommend using this strategy in the
routine clinical setting since infection control measures can
potentially reduce the ESBL prevalence in Enterobacter spp.,
as a clear association was observed per hospital between a high
prevalence and clonal relatedness.
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FIG. 2. ESBL prevalence (A) and clonal relatedness (B) in Enterobacter blood culture isolates (n 271) per participating center. (A) Numbers
on top of bars in panel A indicate the number of ESBL-positive Enterobacter isolates/total number of Enterobacter blood culture isolates per
participating center (*). (B) Center 1, genotype 104 (n  2); center 2, genotype 110 (n  4); center 3, genotype 85 (n  5); center 4, genotype
104 (n  2) and genotype 54 (n  2); center 6, genotype 85 (n  3) (**). Clonal relatedness implicates 98% similarity in DiversiLab typing (9).
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